Viagra User Speaks Out|
Does Sex Hurt The First Time?
How To Bust Weak Erections
Learn Premature Ejaculation Control
Ranbaxy Laboratories Ltd has announced the launch of its benign prostatic hyperplasia (BPH) formulation, Flotral 10 mg or Alternative Tamsulosin formulation . It is a new uro-selective alpha1-blocker, prescription medicine that provides effective medical relief from signs and symptoms of BPH, a urological disorder.
Flotral (alfuzosin), once a day medication, has been developed using the Novel Drug Delivery System (NDDS) technology platform, resulting in better patient compliance, the company said in a statement.
Alfuzosin also has a low risk of sexual side effects whereas erectile dysfunction (ED) and ejaculatory disorders are well-recognised side effects of other alpha-blockers.
If left untreated, BPH can lead to serious health problems, including urinary tract infections , bladder and kidney damage, bladder stones and inability to hold urine, it added.
The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the company's commitment to build its urology franchise through its competitive edge technology of NDDS, Sanjeev I Dani, regional director-India, Ranbaxy, stated.
Ranbaxy's foray into Novel Medical Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries andhas an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.
